• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.29% Nasdaq Down0.03%

    More On 083790.KQ



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    CrystalGenomics, Inc. (083790.KQ)

    12,700.00 Down 250.00(1.93%) May 22, 2:00AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    CrystalGenomics, Inc.
    Tower A, Korea Bio Park
    5th Floor
    Seongnam, 463-400
    South Korea - Map
    Phone: 82 3 1628 2700
    Fax: 82 3 1628 2701
    Website: http://www.cgxinc.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    CrystalGenomics, Inc., a biopharmaceutical company, operates as a structural chemoproteiomics-based drug discovery and development company in South Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles. The company’s drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus that has completed Phase I studies in Europe, as well as is in Phase IIa study in the United States. CrystalGenomics, Inc. is based in Seongnam, South Korea.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on CrystalGenomics, Inc.

    Key Executives 
    Dr. Ho-Jin Chang , 53
    Head of Discovery Biology
    Willim Schmdit ,
    Exec. Officer
    Hui-Sung Lee ,
    Exec. Officer
    Jong-Ryu Choi , 56
    Exec. Officer and Member of Committee of Research Department
    Doh-Young Lee ,
    Exec. Officer
    Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in KRW.